Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report.
Platinum-based chemotherapy is the standard treatment for ovarian cancer, with response rates of 70-80% and pathologic complete remissions of 20-25%. Salvage therapy with paclitaxel has an established role in patients with platinum-refractory ovarian cancer. In non-randomized trials, high doses have tended to be more effective. In this report, we describe two patients with platinum-refractory ovarian cancer who received paclitaxel and had long-term stabilization of their disease. One patient received 250 mg/m2 paclitaxel for 38 cycles; the other 135 mg/m2 for 30 cycles. Both patients received granulocyte colony-stimulating factor (G-CSF) support to prevent severe granulocytopenia; neither experienced cumulative hematopoietic nor neurologic toxicity. Their quality of life was good throughout the treatment.
Balat
O
O
Department of Clinical Investigations, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Kudelka
A P
AP
Tunca
J C
JC
Edwards
C L
CL
Verschraegen
C
C
Kavanagh
J J
JJ
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D017671:Platinum Compounds / Q000627:therapeutic use; D011788:Quality of Life; D016879:Salvage Therapy; D017211:Treatment Failure
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D017671:Platinum Compounds; D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel